Massachusetts Medicaid Lifts Paroxetine Prior Authorization For Children
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s Paxil and Paxil CR continue to require prior authorization under the program. Lifting of prior authorization for pediatric use of paroxetine comes despite FDA’s request that a “black box” warning on pediatric suicidality be added to antidepressant labeling.
You may also be interested in...
FDA Antidepressant Safety Plan Includes "Black Box," Unit-Of-Use Packaging
Unit-of-use packaging will ensure distribution of patient MedGuides, FDA says. Agency asks all antidepressant manufacturers to add "black box" warning, as recommended by advisory committee in September.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states